血液透析中静脉铁剂的安全性:蔗糖铁与葡萄糖酸铁钠的长期比较
该回顾性队列研究利用美国肾脏数据系统,将主要使用蔗糖铁的透析中心与主要使用葡萄糖酸铁钠的透析中心按地区和中心特征进行硬匹配,比较新发血液透析患者的长期结局。共匹配2015对中心、51603例患者,随访49989人年;两组全因、心血管和感染死亡率无显著差异,蔗糖铁中心感染复合终点发生率较低(HR 0.92,95%CI 0.88-0.96),但作者认为可能源于残余混杂、随机机会或因果效应。
要点
- 蔗糖铁与葡萄糖酸铁钠中心的全因、心血管和感染死亡率无显著差异。
- 蔗糖铁中心感染复合终点发生率较低(HR 0.92,95%CI 0.88-0.96)。
- 该差异可能源于残余混杂、随机机会或因果效应,需谨慎解读。
核心结论
- 在新发血液透析患者中,主要使用蔗糖铁与主要使用葡萄糖酸铁钠的透析中心相比,长期结局相似。
- 但蔗糖铁中心患者的感染住院和死亡复合终点有小幅降低,该差异可能源于残余混杂、随机机会或因果效应。
研究设计与样本
- 回顾性队列研究,利用美国肾脏数据系统,按地理区域和中心特征将主要使用葡萄糖酸铁钠的透析中心与主要使用蔗糖铁的相似中心进行硬匹配。
- 共匹配2015对透析中心,51603例新发血液透析患者(蔗糖铁组24911例,葡萄糖酸铁钠组26692例),随访49989人年。
主要发现
- 随访期间共发生10381例死亡,其中心血管死亡3908例,感染死亡1209例。
- 蔗糖铁中心与葡萄糖酸铁钠中心相比,调整后全因死亡HR为0.98(95%CI 0.93-1.03),心血管死亡HR为0.96(95%CI 0.89-1.03),感染死亡HR为0.98(95%CI 0.86-1.13),均无显著差异。
- 在医疗保险受益人中,葡萄糖酸铁钠中心与蔗糖铁中心相比,致死性或非致死性心血管事件HR为1.01(95%CI 0.93-1.09),无显著差异。
- 蔗糖铁中心与葡萄糖酸铁钠中心相比,感染复合终点发生率较低(HR 0.92,95%CI 0.88-0.96)。
局限性
- 非随机治疗分配导致的未观测选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Controversy exists about any differences in longer-term safety across different intravenous iron formulations routinely used in hemodialysis (HD) patients. We exploited a natural experiment to compare outcomes of patients initiating HD therapy in facilities that predominantly (in ≥90% of their patients) used iron sucrose versus sodium ferric gluconate complex. STUDY DESIGN: Retrospective cohort study of incident HD patients. SETTING & PARTICIPANTS: Using the US Renal Data System, we hard-matched on geographic region and center characteristics HD facilities predominantly using ferric gluconate with similar ones using iron sucrose. Subsequently, incident HD patients were assigned to their facility iron formulation exposure. INTERVENTION: Facility-level use of iron sucrose versus ferric gluconate. OUTCOMES: Patients were followed up for mortality from any, cardiovascular, or infectious causes. Medicare-insured patients were followed up for infectious and cardiovascular (stroke or myocardial infarction) hospitalizations and for composite outcomes with the corresponding cause-specific deaths. MEASUREMENTS: HRs. RESULTS: We matched 2,015 iron sucrose facilities with 2,015 ferric gluconate facilities, in which 51,603 patients (iron sucrose, 24,911; ferric gluconate, 26,692) subsequently initiated HD therapy. All recorded patient characteristics were balanced between groups. Over 49,989 person-years, 10,381 deaths (3,908 cardiovascular and 1,209 infectious) occurred. Adjusted all-cause (HR, 0.98; 95% CI, 0.93-1.03), cardiovascular (HR, 0.96; 95% CI, 0.89-1.03), and infectious mortality (HR, 0.98; 95% CI, 0.86-1.13) did not differ between iron sucrose and ferric gluconate facilities. Among Medicare beneficiaries, no differences between ferric gluconate and iron sucrose facilities were observed in fatal or nonfatal cardiovascular events (HR, 1.01; 95% CI, 0.93-1.09). The composite infectious end point occurred less frequently in iron sucrose versus ferric gluconate facilities (HR, 0.92; 95% CI, 0.88-0.96). LIMITATIONS: Unobserved selection bias from nonrandom treatment assignment. CONCLUSIONS: Patients initiating HD therapy in facilities almost exclusively using iron sucrose versus ferric gluconate had similar longer-term outcomes. However, there was a small decrease in infectious hospitalizations and deaths in patients dialyzing in facilities predominantly using iron sucrose. This difference may be due to residual confounding, random chance, or a causal effect.
引用
- Winkelmayer WC, Goldstein BA, Mitani AA, et al. Safety of Intravenous Iron in Hemodialysis: Longer-term Comparisons of Iron Sucrose Versus Sodium Ferric Gluconate Complex. Am J Kidney Dis. 2017. PMID: 28063734. doi:10.1053/j.ajkd.2016.10.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。